1. Home
  2. Directory
  3. Alabama
  4. Birmingham
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1164542221

DR. ROBERT KENNETH LEWIS M.D.
Prescription History 1164542221
Internal Medicine in Birmingham, AL

NPI Status: Active since March 30, 2007

Contact Information

2000 6TH AVE S
BIRMINGHAM, AL
ZIP 35233
Phone: (250) 934-9999

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. ROBERT KENNETH LEWIS M.D., an active Internal Medicine specialist practicing in Birmingham, AL. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 329 documented patient claims. Among these therapy options, the most frequently utilized medication is Eliquis, which accounts for 148 claims alone.

Medication Index

A
E
M
X
No matching medications currently found on file.

Amiodarone Hcl

Generic Formulation: Amiodarone HclSpecialty: Clinical Cardiac Electrophysiology
Provider Metrics Summary
Total Claims 66
30-Day Fills 133.2
Days Supply 3,863
AL State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills98.6
Peer Average Days Supply2,850
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 34.7% more claims than the standard regional baseline profile for AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,062.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.09

State Avg Cost Per Claim

$28.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of serious (possibly fatal) irregular heartbeat (such as recurrent ventricular fibrillation/tachycardia). It is used to restore normal heart rhythm and maintain a regular, steady heartbeat. Amiodarone is known as an anti-arrhythmic drug. It works by blocking certain electrical signals in the heart that can cause an irregular heartbeat.

Eliquis

Generic Formulation: ApixabanSpecialty: Clinical Cardiac Electrophysiology
Provider Metrics Summary
Total Claims 148
30-Day Fills 271.0
Days Supply 8,100
AL State Average Benchmarks
Peer Average Claims100.0
Peer Average 30-Day Fills146.7
Peer Average Days Supply4,096
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 48.0% more claims than the standard regional baseline profile for AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $156,475.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,057.27

State Avg Cost Per Claim

$747.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Metoprolol Succinate

Generic Formulation: Metoprolol SuccinateSpecialty: Clinical Cardiac Electrophysiology
Provider Metrics Summary
Total Claims 96
30-Day Fills 222.0
Days Supply 6,660
AL State Average Benchmarks
Peer Average Claims116.0
Peer Average 30-Day Fills280.8
Peer Average Days Supply8,315
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,003.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.87

State Avg Cost Per Claim

$20.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.

Therapeutic Applications

This medication is a beta-blocker used to treat chest pain (angina), heart failure, and high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This drug works by blocking the action of certain natural chemicals in your body (such as epinephrine) that affect the heart and blood vessels. This lowers heart rate, blood pressure, and strain on the heart.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Clinical Cardiac Electrophysiology
Provider Metrics Summary
Total Claims 19
30-Day Fills 37.0
Days Supply 1,110
AL State Average Benchmarks
Peer Average Claims52.0
Peer Average 30-Day Fills82.2
Peer Average Days Supply2,321
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.5% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $20,755.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,092.41

State Avg Cost Per Claim

$800.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. ROBERT KENNETH LEWIS M.D. provides transparency into local medical care patterns within Birmingham, AL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Internal Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.